0

    531210

    COLINZ

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    COLINZ LABORATORIES LTD. Share Price Today

    Investment Returns

    Over 1 Month 31.84% Over 3 Months 58.35% Over 6 Months 46.47% Over 1 Year 75.84%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    COLINZ LABORATORIES LTD. fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 9.40
    • P/E Ratio (TTM) 18.18
    • Beta 0.27
    • Book Value / share 69.70
    • Return on equity 5.43%
    • EPS (TTM) 4.08
    • Dividend yield [-]%
    • Net profit/quarter (Cr) 0.17
    info icon alternate text

    COLINZ LABORATORIES LTD. Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 1.75
    Operating Expense 1.71
    Net Profit 0.17
    Net Profit Margin (%) 9.71
    Earnings Per Share (EPS) 0.68
    EBITDA 0.27
    Effective Tax Rate (%) 18.18
    Particulars DEC 2025 (Values in Cr)
    Revenue 1.43
    Operating Expense 1.38
    Net Profit 0.08
    Net Profit Margin (%) 5.59
    Earnings Per Share (EPS) 0.33
    EBITDA 0.18
    Effective Tax Rate (%) 30.76
    Particulars SEP 2025 (Values in Cr)
    Revenue 1.39
    Operating Expense 1.36
    Net Profit 0.14
    Net Profit Margin (%) 10.07
    Earnings Per Share (EPS) 0.56
    EBITDA 0.24
    Effective Tax Rate (%) 26.31
    Particulars JUN 2025 (Values in Cr)
    Revenue 1.57
    Operating Expense 1.48
    Net Profit 0.12
    Net Profit Margin (%) 7.64
    Earnings Per Share (EPS) 0.47
    EBITDA 0.21
    Effective Tax Rate (%) 25.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 1.45
    Operating Expense 1.41
    Net Profit 0.15
    Net Profit Margin (%) 10.34
    Earnings Per Share (EPS) 0.60
    EBITDA 0.16
    Effective Tax Rate (%) -25.00
    Particulars MAR 2026 (Values in Cr)
    Revenue 6.14
    Operating Expense 5.93
    Net Profit 0.51
    Net Profit Margin (%) 8.30
    Earnings Per Share (EPS) 2.04
    EBITDA 0.90
    Effective Tax Rate (%) 24.63
    Particulars MAR 2025 (Values in Cr)
    Revenue 6.53
    Operating Expense 6.20
    Net Profit 0.50
    Net Profit Margin (%) 7.65
    Earnings Per Share (EPS) 1.97
    EBITDA 0.79
    Effective Tax Rate (%) 19.35
    Particulars MAR 2024 (Values in Cr)
    Revenue 7.03
    Operating Expense 6.66
    Net Profit 0.49
    Net Profit Margin (%) 6.97
    Earnings Per Share (EPS) 1.93
    EBITDA 0.82
    Effective Tax Rate (%) 24.61
    Particulars MAR 2023 (Values in Cr)
    Revenue 7.15
    Operating Expense 6.72
    Net Profit 0.46
    Net Profit Margin (%) 6.43
    Earnings Per Share (EPS) 1.82
    EBITDA 0.78
    Effective Tax Rate (%) 23.33
    Particulars MAR 2022 (Values in Cr)
    Revenue 6.97
    Operating Expense 6.67
    Net Profit 0.34
    Net Profit Margin (%) 4.87
    Earnings Per Share (EPS) 0.74
    EBITDA 0.76
    Effective Tax Rate (%) 29.16
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 37.61
    ROE % 5.43
    ROCE % 6.72
    Total Debt to Total Equity 0.07
    EBITDA Margin 12.10
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 35.52
    ROE % 5.73
    ROCE % 7.70
    Total Debt to Total Equity 0.05
    EBITDA Margin 11.66
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 32.31
    ROE % 5.81
    ROCE % 7.82
    Total Debt to Total Equity 0.05
    EBITDA Margin 10.91
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 21.69
    ROE % 4.54
    ROCE % 6.78
    Total Debt to Total Equity 0.10
    EBITDA Margin 10.90
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 20.57
    ROE % 2.97
    ROCE % 4.36
    Total Debt to Total Equity 0.10
    EBITDA Margin 8.60
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 5.55
    Total Assets 11.81
    Total Liabilities 11.81
    Total Equity 9.47
    Share Outstanding 0
    Price to Book Ratio 1.93
    Return on Assets (%) 4.20
    Return on Capital (%) 4.91
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 7.00
    Total Assets 11.35
    Total Liabilities 11.35
    Total Equity 8.94
    Share Outstanding 0
    Price to Book Ratio 1.06
    Return on Assets (%) 4.28
    Return on Capital (%) 5.11
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 5.72
    Total Assets 10.23
    Total Liabilities 10.23
    Total Equity 8.13
    Share Outstanding 0
    Price to Book Ratio 1.08
    Return on Assets (%) 4.47
    Return on Capital (%) 5.44
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 5.20
    Total Assets 9.93
    Total Liabilities 9.93
    Total Equity 7.68
    Share Outstanding 0
    Price to Book Ratio 1.09
    Return on Assets (%) 3.41
    Return on Capital (%) 4.15
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 4.68
    Total Assets 10.10
    Total Liabilities 10.10
    Total Equity 7.29
    Share Outstanding 0
    Price to Book Ratio 0.37
    Return on Assets (%) 2.05
    Return on Capital (%) 2.51
    Particulars MAR 2025 (Values in Cr)
    Net Income 0.61
    Cash from Operations -1.24
    Cash from Investing -0.23
    Cash from Financing 0.23
    Net change in Cash -1.45
    Free Cash Flow -0.98
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.65
    Cash from Operations 1.21
    Cash from Investing 0.00
    Cash from Financing 0.22
    Net change in Cash 1.27
    Free Cash Flow 1.21
    Particulars MAR 2023 (Values in Cr)
    Net Income 0.59
    Cash from Operations 0.56
    Cash from Investing 0.00
    Cash from Financing 0.11
    Net change in Cash 0.52
    Free Cash Flow 0.56
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.48
    Cash from Operations 0.61
    Cash from Investing -0.03
    Cash from Financing 0.09
    Net change in Cash 0.52
    Free Cash Flow 0.65
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.24
    Cash from Operations 2.23
    Cash from Investing -0.15
    Cash from Financing 0.08
    Net change in Cash 2.08
    Free Cash Flow 2.39
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.48 13.06 1.52 241.24 23.12 38.85
    BLISS GVS PHARMA LTD 522.90 42.03 4.64 5545.68 118.35 552.90
    CIPLA LTD 1438.55 30.53 3.37 116212.59 1165.55 1672.20
    FERMENTA BIOTECH LTD. 450.85 19.89 3.26 1326.90 256.40 480.00
    GLAXOSMITHKLINE PHARMA LT 2463.55 43.37 18.40 41734.02 2088.00 3258.50
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.48 22.01 4.05 241.24 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 536.60 24.05 4.19 1551.34 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8185.10 106.90 23.44 20462.75 7630.00 9850.00
    BLISS GVS PHARMA LTD 522.90 56.53 4.80 5545.68 118.35 552.90

    COLINZ LABORATORIES LTD. shareholding pattern

    Holding
    49.4%
    50.59%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    COLINZ LABORATORIES LTD. Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    74.95 1.02 redarrow
    red-green-graph indicator
    1 Bearish
    15 Bullish
    • 5 Days 72.00
    • 26 Days 68.10
    • 10 Days 72.10
    • 50 Days 62.40
    • 12 Days 71.80
    • 100 Days 56.90
    • 20 Days 69.80
    • 200 Days 53.40
    72.49 PIVOT
    First Support 70.09 First Resistance 76.59 Second Support 65.99 Second Resistance 78.99 Third Support 63.59 Third Resistance 83.09
    RSI 58.93 ADX 31.91 MACD 3.75 Williams % R -54.62 Commodity Channel Index (CCI) 17.74
    Date 2026-07-14 Week 12703.00 Same Day 1409.00 Month 10222.00
    1 Year 0.27 3 Year 0.35
    Over 1 Month
    31.84% down
    Over 1 Year
    75.84% down
    Over 3 Months
    58.35% down
    Over 3 Years
    26.49% down
    Over 6 Months
    46.47% down
    Over 5 Years
    28.16% down

    COLINZ LABORATORIES LTD. Corporate Actions

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Colinz Laboratories Ltd?

    Answer Field

    Colinz Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 74.95 as on Jul 15 2026 02:01 PM.

    What is the Market Cap of Colinz Laboratories Ltd Share?

    Answer Field

    The market cap of Colinz Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 9.40 as on Jul 15 2026 02:01 PM.

    What is the 52 Week High and Low of Colinz Laboratories Ltd?

    Answer Field

    The 52 Week High and Low of Colinz Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 87.91 and ₹ 36.11.

    What is 1 year return for Colinz Laboratories Ltd?

    Answer Field

    The 1 year returns on the stock has been 75.84%.

    What is the P/E Ratio of Colinz Laboratories Ltd Share?

    Answer Field

    As on Jul 15 2026 02:01 PM the price-to-earnings (PE) ratio for Colinz Laboratories Ltd share is 18.18.

    What is the PB ratio of Colinz Laboratories Ltd Share?

    Answer Field

    As on Jul 15 2026 02:01 PM, the price-to-book (PB) ratio for Colinz Laboratories Ltd share is 69.70.

    How to Buy Colinz Laboratories Ltd Share?

    Answer Field

    You can trade in Colinz Laboratories Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Colinz Laboratories Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Colinz Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Colinz Laboratories Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |